Acellular Tissue Engineered Vessel for Hemodialysis Access

Mohamad A. Hussain, MD, PhD, a vascular surgeon, was at ASN Kidney Week to present the late-breaking abstract “Prospective Randomized Trial of Humacyte’s Acellular Tissue Engineered Vessel Versus Autologous Arteriovenous Fistula for Hemodialysis Access.” This was a phase 3 clinical trial of the acellular tissue engineered vessel (ATEV) in arteriovenous access for patients with end-stage renal disease. Dr. Hussain joined Joel Topf, MD, for a chat about the study’s findings.